申请人:Luo Guanglin
公开号:US08748429B2
公开(公告)日:2014-06-10
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
本文披露了一种新型化合物I的公开,其中包括药用可接受的盐,这些化合物是CGRP受体拮抗剂。本文还涉及药物组成物和使用这些化合物治疗与CGRP相关的疾病的方法,包括偏头痛和其他头痛,神经源性血管扩张,神经源性炎症,热伤害,循环性休克,与绝经期相关的潮红,气道炎症性疾病如哮喘和慢性阻塞性肺疾病(COPD)。